a novel assay for detecting the mutation of nucleotide 1758-1777 deletion in core promoter region of hepatitis b virus
Clicks: 167
ID: 212961
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
167 views
36 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #99 of 124 articles by views in frontiers in neurorobotics
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 124 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Objective Nucleotide (nt) 1758-1777 deletion in core promoter (CP) region of hepatitis B virus (HBV) has been suggested to be associated with disease progression. However, the complicated and less sensitive assay for it limited its use in clinic. The present study was aimed at setting a novel assay for its detection using single-tube nested PCR amplification and real-time PCR melting curve analysis. Methods The PCR primers were designed through analysis of HBV genomic sequences in GenBank, and detection conditions were optimized. HBV CP region from 340 serum samples of chronic hepatitis B patients were amplified and directly sequenced, and fifty samples were randomly selected for cloning and sequencing for analysis of nt 1758-1777 deletion. The wild-type and deletion-type plasmids were extracted from mono-cloning samples. Positive standard of melting curve analysis was set up in light of the results of PCR amplification of two standard plasmids and cloning samples. The new method of assay was used in 340 samples, and the data were verified by the results of pyrosequencing. Results Sixteen (4.7%) samples were positive for the deletion by direct sequencing, and no less than 15% samples in standard plasmids and cloning sequencing showed sequence deletion. The melting temperature (Tm) of deletion-type plasmid and cloning samples containing ≥15% proportion of the deletion sequence was ≥88.3℃, which was determined as positive standard of the novel assay. Forty-seven (13.8%) samples were detected positive for nt 1758-1777 deletion by the novel assay. Among them, deletion ratio was ≥1.0% in 38 samples and <1.0% in 9 samples by pyrosequencing, respectively. The deletion ratio was all <1.0% in 15 negative control samples. The deletion ratio of 1.0% was taken as positive cutoff by pyrosequencing, the novel assay had 80.9% positive consistency and 100% negative consistency, with a Kappa value of 0.671. Conclusions Comparing with direct sequencing, the novel assay significantly increased detection rate of nt 1758-1777 deletion. In combination with pyrosequencing for confirmation, the accuracy and cost-effectiveness of the detection could be significantly improved. The novel assay offers an example for detecting HBV genetic deletions.
DOI: 10.11855/j.issn.0577-7402.2016.03.04
| Reference Key |
nian2016medicala
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Xue-yuan NIAN;Zhi-hui XU;Yan LIU;Xiao-dong LI;Jian-hong CHEN;Ya-qun QIN;Hao LIAO;Dong-ping XU |
| Journal | frontiers in neurorobotics |
| Year | 2016 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.